First Light Asset Management LLC raised its position in shares of AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 42.1% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,964,703 shares of the medical device company’s stock after acquiring an additional 581,843 shares during the period. AtriCure makes up approximately 3.9% of First Light Asset Management LLC’s investment portfolio, making the stock its 7th largest position. First Light Asset Management LLC owned about 4.13% of AtriCure worth $44,736,000 at the end of the most recent reporting period.
Other institutional investors also recently made changes to their positions in the company. Comerica Bank boosted its stake in AtriCure by 70.5% in the 1st quarter. Comerica Bank now owns 2,522 shares of the medical device company’s stock valued at $77,000 after purchasing an additional 1,043 shares during the period. Quest Partners LLC acquired a new stake in shares of AtriCure during the fourth quarter worth $103,000. Virtu Financial LLC bought a new stake in shares of AtriCure in the fourth quarter valued at about $213,000. Victory Capital Management Inc. grew its stake in shares of AtriCure by 22.9% in the fourth quarter. Victory Capital Management Inc. now owns 6,202 shares of the medical device company’s stock valued at $221,000 after acquiring an additional 1,155 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC grew its position in shares of AtriCure by 32.1% during the 2nd quarter. Mount Yale Investment Advisors LLC now owns 9,743 shares of the medical device company’s stock worth $222,000 after purchasing an additional 2,368 shares in the last quarter. Institutional investors own 99.11% of the company’s stock.
Insider Buying and Selling
In other AtriCure news, Director Maggie Yuen sold 3,500 shares of the company’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $24.07, for a total value of $84,245.00. Following the completion of the transaction, the director now directly owns 8,970 shares in the company, valued at approximately $215,907.90. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 3.20% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Read Our Latest Stock Analysis on AtriCure
AtriCure Stock Performance
Shares of AtriCure stock opened at $29.05 on Tuesday. The company’s 50 day moving average price is $24.67 and its two-hundred day moving average price is $24.57. The firm has a market capitalization of $1.38 billion, a P/E ratio of -36.31 and a beta of 1.43. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.13 and a quick ratio of 2.93. AtriCure, Inc. has a fifty-two week low of $18.94 and a fifty-two week high of $44.64.
AtriCure (NASDAQ:ATRC – Get Free Report) last issued its quarterly earnings data on Tuesday, July 30th. The medical device company reported ($0.17) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.17). AtriCure had a negative return on equity of 8.39% and a negative net margin of 9.33%. The business had revenue of $116.27 million for the quarter, compared to analyst estimates of $116.24 million. During the same quarter in the previous year, the company posted ($0.12) EPS. AtriCure’s quarterly revenue was up 15.2% compared to the same quarter last year. On average, equities analysts forecast that AtriCure, Inc. will post -0.77 earnings per share for the current fiscal year.
About AtriCure
AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.
Read More
- Five stocks we like better than AtriCure
- Market Cap Calculator: How to Calculate Market Cap
- Rate Cut Shockwaves: Which Bank Stocks Will Rise or Fall?
- What Investors Need to Know About Upcoming IPOs
- S&P 500 Shake-Up: New Entrants Driving Market Momentum
- Why Are Stock Sectors Important to Successful Investing?
- Don’t Overlook Mosaic’s Challenges—They Might Spark Opportunity
Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC – Free Report).
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.